In between TO and other possible stated deals by Nader, I’m expecting a total of $50M plus in the bank by the end of Q3. As you know Nader is always selling the glass half full so I’m conditioned to add extra time but fully believe many plates are spinning with real interest.
I understand your opinion on Naders competency. My frustration with progress on financing reached a threshold about a month ago so I made calls to ease my tension. What I can tell you is moves like Dr. Rae to focus on partners and licensing deals is a reflection of the BOD understanding of Nader’s strengths and weaknesses. In fairness to Nader he is spread extremely thin and has been running at a very steep pace for many years.
IMO Nader has the experience to navigate the FDA and will lay proof with approval of Combo. On the other hand he needs to make way for Dr. Rae on the partnership, licensing, and non dilutive financing front.
We are not the only ones wanting to see the financing dilemma resolved - the BOD have a lot of skin in the game and you can bet they are understanding the importance of building an experienced team that can more effectively negotiate such deals.
Often times it is difficult to see clearly when we are too close to the fire. Leronlimab is Nader’s paternal baby and his ability to be objective may be a barrier to negotiating effectively in addition to his delivery. I know the feeling I get with his lack of patience and arrogance on the conference calls. I’m sure this personality trait has been recognized by the BOD.
From my perspective it appears the BOD shares many of the same concerns communicated here and they are taking action.
Market Data 
Markets 
AI
